Skip to main content

Research Repository

Advanced Search

Evaluation of Decreased Kidney Function in Dogs Receiving Carboplatin: A Retrospective Cohort Study of 98 Dogs (2006–2024)

Yale, Andrew; So, Alvina; Guillen, Alexandra; Desmas-Bazelle, Isabelle; Rogato, Francesco; Jepson, Rosanne

Authors

Andrew Yale

Alvina So

Alexandra Guillen

Isabelle Desmas-Bazelle

Francesco Rogato

Rosanne Jepson



Abstract

Decreased kidney function is observed in some people receiving carboplatin, but limited literature explores this in dogs. The aim of this study was to evaluate the incidence and risk factors for decreased kidney function in dogs receiving carboplatin. A single-institute retrospective cohort study compared the incidence of decreased kidney function between non-azotaemic dogs receiving carboplatin and an age- and weight-matched cancer-bearing control group not receiving chemotherapy. Change in creatinine concentration and a linear mixed effects model were used to compare trends in creatinine between groups. Decreased kidney function was defined as a sustained increase in creatinine ≥ 26.5 μmol/L on ≥ 2 consecutive measurements compared to baseline; the VCOG-CTCAE v2 grading system for increased creatinine was also applied. Risk factors were explored. Ninety-eight dogs were included (n = 49/group). There was no difference in median change in creatinine concentration (+2.0 μmol/L; p = 0.311) or creatinine trends (p = 0.958) across the study period between groups. Incidence of decreased kidney function was low and did not significantly differ between groups (carboplatin group n = 4 [8.2%]; control group n = 2 [4.1%]; p = 0.678); no risk factors were identified. There was no difference in the frequency of VCOG grade one (p = 0.731), two (p = 0.641) or three (p = 0.429) creatinine adverse events between groups. Non-azotaemic dogs receiving carboplatin do not have a significantly increased short-term risk of decreased kidney function compared to those not receiving chemotherapy, although the numerical increase in incidence in dogs receiving carboplatin could be clinically relevant. Larger studies should aim to explore this further and investigate carboplatin's impact on subclinical and long-term renal function.

Citation

Yale, A., So, A., Guillen, A., Desmas-Bazelle, I., Rogato, F., & Jepson, R. (2025). Evaluation of Decreased Kidney Function in Dogs Receiving Carboplatin: A Retrospective Cohort Study of 98 Dogs (2006–2024). Veterinary and Comparative Oncology, https://doi.org/10.1111/vco.13069

Journal Article Type Article
Acceptance Date May 20, 2025
Online Publication Date Jun 5, 2025
Publication Date Jun 5, 2025
Deposit Date Jun 5, 2025
Publicly Available Date Jun 5, 2025
Print ISSN 1476-5810
Electronic ISSN 1476-5829
Publisher British Veterinary Oncology Study Group
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1111/vco.13069

Files




You might also like



Downloadable Citations